StartDRREDDY • NSE
add
Dr Reddy's Laboratories Ltd
Seneste lukkekurs
1.195,35 ₹
Dagsinterval
1.193,60 ₹ - 1.223,20 ₹
Årsinterval
1.074,00 ₹ - 1.421,49 ₹
Markedsværdi
1,01 bio. INR
Gns. volumen
1,48 mio.
P/E-værdi
18,96
Udbytteprocent
0,66 %
Primær børs
NSE
I nyhederne
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(INR) | sep. 2024info | År til år-ændring |
---|---|---|
Indtægt | 80,16 mia. | 16,51 % |
Driftsudgifter | 29,72 mia. | 24,54 % |
Nettoindtægt | 12,55 mia. | -15,18 % |
Overskudsgrad | 15,66 | -27,20 % |
Earnings per share | 15,83 | -11,13 % |
EBITDA | 22,02 mia. | 8,53 % |
Effektiv afgiftssats | 30,01 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(INR) | sep. 2024info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 63,07 mia. | -7,15 % |
Samlede aktiver | 465,96 mia. | 34,27 % |
Samlede passiver | 156,67 mia. | 66,79 % |
Samlet egenkapital | 309,28 mia. | — |
Shares outstanding | 833,05 mio. | — |
Kurs/indre værdi | 3,26 | — |
Afkast af aktiver | 10,24 % | — |
Afkast af kapital | 13,21 % | — |
Pengestrøm
Nettoændring i likviditet
(INR) | sep. 2024info | År til år-ændring |
---|---|---|
Nettoindtægt | 12,55 mia. | -15,18 % |
Pengestrøm fra drift | 9,32 mia. | -48,03 % |
Pengestrøm fra investering | -19,07 mia. | -322,21 % |
Pengestrøm fra finansiering | 16,15 mia. | 329,53 % |
Nettoændring i likviditet | 6,37 mia. | 1,03 % |
Fri pengestrøm | 3,92 mia. | -72,47 % |
Om
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Administrerende direktør
Grundlagt
1984
Hovedkvarter
Website
Ansatte
27.048